Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

Researchers at the Josep Carreras Leukaemia Research Institute have demonstrated that combining data from different origins ...

The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and ...

Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often ...

The CAR-T Cellular Team at Children’s Hospital of The King’s Daughters is making it easier for children — and their families ...

Engineered immune cells spark cancer immunotherapy hope, following metabolic by-products secreted by cancer cells to ...

In this Q&A with The American Journal of Managed Care® ( AJMC® ), panelist Turab Mohammed, MD, a hematologist-oncologist at ...

A recent biobank cohort analysis published in the Journal of the American Medical Association revealed that clonal hematopoiesis of indeterminate potential (CHIP) was identified as a risk ...

By partnering with other like-minded organizations to fund targeted RFAs throughout the year, ACS is able to invest in new ...

Biomea Fusion, Inc. ( BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes March 30, 2026 3:00 PM EDT Michael J. Hitchcock - Interim CEO & Director Ramses Erdtmann - ...